Concepedia

Ken Jarvis

KJ

Statistics

Publications

8

Citations

1.2K

H-Index

8

Active since

1998

Affiliations

Abbott Fund(Current)

Abbott (United Kingdom)

Ken Jarvis is an author at Abbott Fund specializing in pharmacology, chemotherapy, and poly(adp-ribose) polymerase inhibitors.

Publications per year

1998–2008

8

Publications

8

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

, , +15

A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i>

Alex R. Shoemaker, Anatol Oleksijew, Joy Bauch et al. · Cancer Research · 2006 · 146 citations

, , +10

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Xuesong Liu, Yan Shi, Ran Guan et al. · Molecular Cancer Research · 2008 · 76 citations

, , +17

New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models

Bruce G. Szczepankiewicz, Gang Liu, Hwan-Soo Jae et al. · Journal of Medicinal Chemistry · 2001 · 66 citations

, , +16

Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers

Gui‐Dong Zhu, Viraj B. Gandhi, Jianchun Gong et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 49 citations · Full text

, , +9

1–5 of 8